

# Jerzy BeÅ,towski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1391011/publications.pdf>

Version: 2024-02-01

104  
papers

3,991  
citations

147566

31  
h-index

123241

61  
g-index

106  
all docs

106  
docs citations

106  
times ranked

5621  
citing authors

#	ARTICLE	IF	CITATIONS
1	Role of Hydrogen Sulfide and Polysulfides in the Regulation of Lipolysis in the Adipose Tissue: Possible Implications for the Pathogenesis of Metabolic Syndrome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1346.	1.8	6
2	Effect of Exogenous Hydrogen Sulfide and Polysulfide Donors on Insulin Sensitivity of the Adipose Tissue. <i>Biomolecules</i> , 2022, 12, 646.	1.8	6
3	Salt Intake, Aldosterone Secretion, and Obesity: Role in the Pathogenesis of Resistant Hypertension. <i>American Journal of Hypertension</i> , 2021, 34, 588-590.	1.0	3
4	Paraoxonase 1 Phenotype and Protein N-Homocysteinylation in Patients with Rheumatoid Arthritis: Implications for Cardiovascular Disease. <i>Antioxidants</i> , 2020, 9, 899.	2.2	8
5	Cladribine Treatment Improved Homocysteine Metabolism and Increased Total Serum Antioxidant Activity in Secondary Progressive Multiple Sclerosis Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-7.	1.9	5
6	A novel miRNA-4484 is up-regulated on microarray and associated with increased MMP-21 expression in serum of systemic sclerosis patients. <i>Scientific Reports</i> , 2019, 9, 14264.	1.6	14
7	Synthesis, Metabolism, and Signaling Mechanisms of Hydrogen Sulfide: An Overview. <i>Methods in Molecular Biology</i> , 2019, 2007, 1-8.	0.4	47
8	Short-term follow-up BNP level and risk stratification after myocardial infarction. <i>International Journal of Cardiology</i> , 2019, 291, 173-174.	0.8	3
9	The effect of exenatide (a GLP-1 analog) and sitagliptin (a DPP-4 inhibitor) on plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and concentration in normal and fructose-fed rats. <i>European Journal of Pharmacology</i> , 2019, 850, 180-189.	1.7	6
10	Epicardial adipose tissue: The new target for statin therapy. <i>International Journal of Cardiology</i> , 2019, 274, 353-354.	0.8	5
11	Hydrogen sulfide in the regulation of insulin secretion and insulin sensitivity: Implications for the pathogenesis and treatment of diabetes mellitus. <i>Biochemical Pharmacology</i> , 2018, 149, 60-76.	2.0	67
12	Metabolic Effects of Metformin in the Failing Heart. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2869.	1.8	61
13	Serum paraoxonase 1 activity and protein N-homocysteinylation in primary human endometrial cancer. <i>Tumor Biology</i> , 2018, 40, 101042831879786.	0.8	9
14	Role of progranulin in the regulation of vascular tone: (patho)physiological implications. <i>Acta Physiologica</i> , 2017, 219, 706-708.	1.8	3
15	Processes of plasma protein N-homocysteinylation in multiple sclerosis. <i>International Journal of Neuroscience</i> , 2017, 127, 709-715.	0.8	8
16	Hydrogen Sulfide in the Adipose Tissue—Physiology, Pathology and a Target for Pharmacotherapy. <i>Molecules</i> , 2017, 22, 63.	1.7	35
17	Progranulin, a New Adipokine at the Crossroads of Metabolic Syndrome, Diabetes, Dyslipidemia and Hypertension. <i>Current Pharmaceutical Design</i> , 2017, 23, 1533-1539.	0.9	28
18	Modulation of paraoxonase 1 (PON1) activity and protein N-homocysteinylation by bisphosphonates in rats. <i>Chemico-Biological Interactions</i> , 2016, 259, 401-406.	1.7	3

#	ARTICLE	IF	CITATIONS
19	The paraoxonase 1 (PON1), platelet-activating factor acetylhydrolase (PAF-AH) and dimethylarginine dimethylaminohydrolase (DDAH) activity in the metformin treated normal and diabetic rats. <i>European Journal of Pharmacology</i> , 2016, 789, 187-194.	1.7	9
20	Effects of antiretroviral treatment on paraoxonase 1 (PON1) activity in rats. <i>Chemico-Biological Interactions</i> , 2016, 259, 407-412.	1.7	3
21	Hydrogen sulfide in pharmacology and medicine – An update. <i>Pharmacological Reports</i> , 2015, 67, 647-658.	1.5	124
22	Hydrogen-sulfide-mediated vasodilatory effect of nucleoside 5'-monophosphorothioates in perivascular adipose tissue. <i>Canadian Journal of Physiology and Pharmacology</i> , 2015, 93, 585-595.	0.7	15
23	Triactome: Neuro-Immune-Adipose Interactions. Implication in Vascular Biology. <i>Frontiers in Immunology</i> , 2014, 5, 130.	2.2	24
24	Editorial: Leptin and the Cardiovascular System - A Target for Therapeutic Interventions. <i>Current Pharmaceutical Design</i> , 2014, 20, 601-602.	0.9	2
25	Hydrogen Sulfide and Endothelium-Dependent Vasorelaxation. <i>Molecules</i> , 2014, 19, 21183-21199.	1.7	78
26	Reverse epidemiology in ischemic stroke: high cholesterol as a predictor of improved survival in stroke patients. <i>Clinical Lipidology</i> , 2014, 9, 135-139.	0.4	3
27	Corrigendum to "Nucleoside monophosphorothioates as the new hydrogen sulfide precursors with unique properties" [Pharmacol. Res. 81 (2014) 34-43]. <i>Pharmacological Research</i> , 2014, 87, 166.	3.1	0
28	Nucleoside monophosphorothioates as the new hydrogen sulfide precursors with unique properties. <i>Pharmacological Research</i> , 2014, 81, 34-43.	3.1	8
29	Serum paraoxonase-1 activity of dairy Holstein-Friesian cows in different lactation stages – preliminary study. <i>Polish Journal of Veterinary Sciences</i> , 2014, 17, 143-147.	0.2	9
30	An Integrated View: Neuroadipocrinology of Diabetes. <i>Serbian Journal of Experimental and Clinical Research</i> , 2014, 15, 61-69.	0.2	7
31	Leptin-Induced Endothelium-Dependent Vasorelaxation of Peripheral Arteries in Lean and Obese Rats: Role of Nitric Oxide and Hydrogen Sulfide. <i>PLoS ONE</i> , 2014, 9, e86744.	1.1	50
32	Hydrogen sulfide (H <sub>2</sub> S): the new member of gasotransmitter family. <i>Biomedical Reviews</i> , 2014, 18, 75.	0.6	4
33	Adipose tissue and homocysteine metabolism. <i>Biomedical Reviews</i> , 2014, 20, 7.	0.6	1
34	Adipobiology of stem cell-based therapy: secretome insight. <i>Biomedical Reviews</i> , 2014, 21, 57.	0.6	4
35	Transactivation of ErbB Receptors by Leptin in the Cardiovascular System: Mechanisms, Consequences and Target for Therapy. <i>Current Pharmaceutical Design</i> , 2014, 20, 616-624.	0.9	17
36	Role of epidermal growth factor receptor in the pathogenesis and treatment of arterial hypertension. <i>Biomedical Reviews</i> , 2014, 18, 1.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Endogenous hydrogen sulfide in perivascular adipose tissue: role in the regulation of vascular tone in physiology and pathology. <i>Canadian Journal of Physiology and Pharmacology</i> , 2013, 91, 889-898.	0.7	44
38	Paraoxonase 1 activity in multiple sclerosis patients during mitoxantrone therapy. <i>Acta Neurologica Scandinavica</i> , 2013, 127, e33-e36.	1.0	5
39	Thiazolidinedione-Induced Fluid Retention: Recent Insights into the Molecular Mechanisms. <i>PPAR Research</i> , 2013, 2013, 1-8.	1.1	50
40	Modulation of H <sub>2</sub> S Metabolism by Statins: A New Aspect of Cardiovascular Pharmacology. <i>Antioxidants and Redox Signaling</i> , 2012, 17, 81-94.	2.5	27
41	Adipoparacrinology: an Emerging Field in Biomedical Research. <i>Balkan Medical Journal</i> , 2012, 29, 2-9.	0.3	13
42	Leptin and the regulation of endothelial function in physiological and pathological conditions. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2012, 39, 168-178.	0.9	95
43	Adipoparacrinology of Atherosclerosis: Evidence Updated. <i>Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry</i> , 2012, 12, 2-7.	0.5	0
44	Differential effects of statins on endogenous H <sub>2</sub> S formation in perivascular adipose tissue. <i>Pharmacological Research</i> , 2011, 63, 68-76.	3.1	85
45	Opposite effects of pravastatin and atorvastatin on insulin sensitivity in the rat: Role of vitamin D metabolites. <i>Atherosclerosis</i> , 2011, 219, 526-531.	0.4	19
46	Leptin Signaling in Blood Platelets as a Target for Therapeutic Intervention. <i>Current Signal Transduction Therapy</i> , 2011, 6, 20-28.	0.3	0
47	Inhibition of cell proliferation: a new role of liver X receptors. <i>Clinical Lipidology</i> , 2011, 6, 137-141.	0.4	3
48	Effect of Leptin on Vascular Nitric Oxide and Endothelial Function. <i>Current Hypertension Reviews</i> , 2010, 6, 1-7.	0.5	0
49	Leptin and the Regulation of Renal Sodium Handling and Renal Na <sup>+</sup> -Transporting ATPases: Role in the Pathogenesis of Arterial Hypertension. <i>Current Cardiology Reviews</i> , 2010, 6, 31-40.	0.6	23
50	Hypoxia in the Renal Medulla: Implications for Hydrogen Sulfide Signaling. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2010, 334, 358-363.	1.3	75
51	Modulation of paraoxonase 1 and protein N-homocysteinylation by leptin and the synthetic liver X receptor agonist T0901317 in the rat. <i>Journal of Endocrinology</i> , 2010, 204, 191-198.	1.2	22
52	Hydrogen Sulfide and its Modulation in Arterial Hypertension and Atherosclerosis. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2010, 8, 173-186.	0.4	18
53	Liver X receptor (LXR) and the reproductive system – a potential novel target for therapeutic intervention. <i>Pharmacological Reports</i> , 2010, 62, 15-27.	1.5	32
54	The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylhydrolase activity. <i>Life Sciences</i> , 2010, 87, 126-132.	2.0	18

#	ARTICLE	IF	CITATIONS
55	Chronic hyperleptinemia induces resistance to acute natriuretic and NO-mimetic effects of leptin. <i>Peptides</i> , 2010, 31, 155-163.	1.2	19
56	Statins and ALS: the possible role of impaired LXR signaling. <i>Medical Science Monitor</i> , 2010, 16, RA73-78.	0.5	5
57	Adverse Effects of Statins - Mechanisms and Consequences. <i>Current Drug Safety</i> , 2009, 4, 209-228.	0.3	179
58	EGF Receptor as a Drug Target in Arterial Hypertension. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 526-538.	1.1	15
59	Paraoxonase 1 activity in different types of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009, 15, 399-402.	1.4	45
60	Resistance to acute NO-mimetic and EDHF-mimetic effects of leptin in the metabolic syndrome. <i>Life Sciences</i> , 2009, 85, 557-567.	2.0	26
61	Renal antioxidant enzymes and glutathione redox status in leptin-induced hypertension. <i>Molecular and Cellular Biochemistry</i> , 2008, 319, 163-174.	1.4	19
62	Transactivation of epidermal growth factor receptor in vascular and renal systems in rats with experimental hyperleptinemia: Role in leptin-induced hypertension. <i>Biochemical Pharmacology</i> , 2008, 75, 1623-1638.	2.0	24
63	Role of extracellular signal-regulated kinases (ERK) in leptin-induced hypertension. <i>Life Sciences</i> , 2008, 82, 402-412.	2.0	19
64	Gamma-MSH/MC3R natriuretic signaling system: The possible explanation for contrasting blood pressure effects of agouti mutation and melanocortin receptor knockout. <i>Bioscience Hypotheses</i> , 2008, 1, 243-247.	0.2	1
65	Liver X Receptors (LXR) as Therapeutic Targets in Dyslipidemia. <i>Cardiovascular Therapeutics</i> , 2008, 26, 297-316.	1.1	111
66	Central vs. peripheral leptin excess in the pathogenesis of obesity-associated hypertension. <i>Journal of Hypertension</i> , 2008, 26, 827-828.	0.3	9
67	Adiponectin and its Role in Cardiovascular Diseases. <i>Cardiovascular &amp; Hematological Disorders Drug Targets</i> , 2008, 8, 7-46.	0.2	66
68	Regulation of Renal Ouabain-Resistant Na <sup>+</sup> -ATPase by Leptin, Nitric Oxide, Reactive Oxygen Species, and Cyclic Nucleotides: Implications for Obesity-Associated Hypertension. <i>Clinical and Experimental Hypertension</i> , 2007, 29, 189-207.	0.5	31
69	Role of PI3K and PKB/Akt in acute natriuretic and NO-mimetic effects of leptin. <i>Regulatory Peptides</i> , 2007, 140, 168-177.	1.9	12
70	Hydrogen sulfide (H <sub>2</sub> S) - the third gas of interest for pharmacologists. <i>Pharmacological Reports</i> , 2007, 59, 4-24.	1.5	438
71	Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism. <i>Postepy Higieny I Medycyny Doswiadczonej</i> , 2007, 61, 736-59.	0.1	94
72	Liver X receptors (LXRs). Part II: non-lipid effects, role in pathology, and therapeutic implications. <i>Postepy Higieny I Medycyny Doswiadczonej</i> , 2007, 61, 760-85.	0.1	21

#	ARTICLE	IF	CITATIONS
73	Leptin and atherosclerosis. <i>Atherosclerosis</i> , 2006, 189, 47-60.	0.4	421
74	Role of nitric oxide and endothelium-derived hyperpolarizing factor (EDHF) in the regulation of blood pressure by leptin in lean and obese rats. <i>Life Sciences</i> , 2006, 79, 63-71.	2.0	28
75	H <sub>2</sub> O <sub>2</sub> and Src-dependent transactivation of the EGF receptor mediates the stimulatory effect of leptin on renal ERK and Na <sup>+</sup> , K <sup>+</sup> -ATPase. <i>Peptides</i> , 2006, 27, 3234-3244.	1.2	26
76	Role of leptin in blood pressure regulation and arterial hypertension. <i>Journal of Hypertension</i> , 2006, 24, 789-801.	0.3	178
77	TIME-DEPENDENT TRANSITION FROM H <sub>2</sub> O <sub>2</sub> EXTRACELLULAR SIGNAL-REGULATED KINASE- TO O <sub>2</sub> NITRIC OXIDE-DEPENDENT MECHANISMS IN THE STIMULATORY EFFECT OF LEPTIN ON RENAL Na <sup>+</sup> /K <sup>+</sup> -ATPase IN THE RAT. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2006, 33, 1216-1224.	0.9	12
78	Phosphodiesterase 5 Inhibitor Ameliorates Renal Resistance to Atrial Natriuretic Peptide Associated with Obesity and Hyperleptinemia. <i>Archives of Medical Research</i> , 2006, 37, 307-315.	1.5	9
79	Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy. <i>Pharmacological Reports</i> , 2006, 58, 159-78.	1.5	89
80	Apelin and visfatin: unique "beneficial" adipokines upregulated in obesity?. <i>Medical Science Monitor</i> , 2006, 12, RA112-9.	0.5	68
81	Effect of hyperleptinemia on endothelial nitric oxide production. <i>Atherosclerosis</i> , 2005, 178, 403-404.	0.4	8
82	Statins and Modulation of Oxidative Stress. <i>Toxicology Mechanisms and Methods</i> , 2005, 15, 61-92.	1.3	39
83	Antioxidant treatment normalizes nitric oxide production, renal sodium handling and blood pressure in experimental hyperleptinemia. <i>Life Sciences</i> , 2005, 77, 1855-1868.	2.0	19
84	Differential effect of antioxidant treatment on plasma and tissue paraoxonase activity in hyperleptinemic rats. <i>Pharmacological Research</i> , 2005, 51, 523-532.	3.1	37
85	Time-dependent effect of leptin on renal Na <sup>+</sup> ,K <sup>+</sup> -ATPase activity.. <i>Acta Biochimica Polonica</i> , 2005, 52, 803-810.	0.3	10
86	Antioxidant treatment normalizes renal Na <sup>+</sup> ,K <sup>+</sup> -ATPase activity in leptin-treated rats. <i>Pharmacological Reports</i> , 2005, 57, 219-28.	1.5	15
87	Time-dependent effect of leptin on renal Na <sup>+</sup> ,K <sup>+</sup> -ATPase activity. <i>Acta Biochimica Polonica</i> , 2005, 52, 803-9.	0.3	3
88	Protein homocysteinylation: a new mechanism of atherogenesis?. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2005, 59, 392-404.	0.1	31
89	Effect of 3-hydroxy-3-methylglutarylcoenzyme A Reductase Inhibitors (Statins) on Tissue Paraoxonase 1 and Plasma Platelet Activating Factor Acetylhydrolase Activities. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 43, 121-127.	0.8	31
90	Influence of intravenously administered leptin on nitric oxide production, renal hemodynamics and renal function in the rat. <i>Regulatory Peptides</i> , 2004, 120, 59-67.	1.9	30

#	ARTICLE	IF	CITATIONS
91	Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. <i>Life Sciences</i> , 2004, 74, 2987-3000.	2.0	94
92	Bidirectional regulation of renal cortical Na <sup>+</sup> ,K <sup>+</sup> -ATPase by protein kinase C.. <i>Acta Biochimica Polonica</i> , 2004, 51, 757-772.	0.3	19
93	Adrenomedullin--what do we know 10 years since its discovery?. <i>Polish Journal of Pharmacology</i> , 2004, 56, 5-27.	0.3	94
94	Up-regulation of renal Na <sup>+</sup> , K <sup>+</sup> -ATPase: the possible novel mechanism of leptin-induced hypertension. <i>Polish Journal of Pharmacology</i> , 2004, 56, 213-22.	0.3	16
95	Stimulatory Effect of Leptin on Nitric Oxide Production Is Impaired in Dietary-Induced Obesity. <i>Obesity</i> , 2003, 11, 1571-1580.	4.0	16
96	Leptin decreases plasma paraoxonase 1 (PON1) activity and induces oxidative stress: the possible novel mechanism for proatherogenic effect of chronic hyperleptinemia. <i>Atherosclerosis</i> , 2003, 170, 21-29.	0.4	147
97	Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males. <i>Atherosclerosis</i> , 2002, 164, 283-288.	0.4	49
98	Human Leptin Stimulates Systemic Nitric Oxide Production in the Rat. <i>Obesity</i> , 2002, 10, 939-946.	4.0	53
99	Spectrophotometric method for the determination of renal ouabain-sensitive H <sup>+</sup> ,K <sup>+</sup> -ATPase activity.. <i>Acta Biochimica Polonica</i> , 2002, 49, 515-527.	0.3	18
100	Regulation of renal tubular sodium transport by cardiac natriuretic peptides: two decades of research. <i>Medical Science Monitor</i> , 2002, 8, RA39-52.	0.5	32
101	Human leptin administered intraperitoneally stimulates natriuresis and decreases renal medullary Na <sup>+</sup> , K <sup>+</sup> -ATPase activity in the rat – impaired effect in dietary-induced obesity. <i>Medical Science Monitor</i> , 2002, 8, BR221-9.	0.5	35
102	Cerivastatin modulates plasma paraoxonase/arylesterase activity and oxidant-antioxidant balance in the rat. <i>Polish Journal of Pharmacology</i> , 2002, 54, 143-50.	0.3	8
103	Spectrophotometric method for the determination of renal ouabain-sensitive H <sup>+</sup> ,K <sup>+</sup> -ATPase activity. <i>Acta Biochimica Polonica</i> , 2002, 49, 515-27.	0.3	6
104	Differential effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on plasma paraoxonase 1 activity in the rat. <i>Polish Journal of Pharmacology</i> , 2002, 54, 661-71.	0.3	12